IV 
115TH CONGRESS 
1ST SESSION 
H. RES. 420 
Expressing support for the designation of the week of July 9 through July 
15, 2017, as ‘‘Sarcoma Awareness Week’’ and July 15, 2017, as 
‘‘Leiomyosarcoma Awareness Day’’. 
IN THE HOUSE OF REPRESENTATIVES 
JUNE 28, 2017 
Mr. LEVIN submitted the following resolution; which was referred to the 
Committee on Energy and Commerce 
RESOLUTION 
Expressing support for the designation of the week of July 
9 through July 15, 2017, as ‘‘Sarcoma Awareness Week’’ 
and July 15, 2017, as ‘‘Leiomyosarcoma Awareness 
Day’’. 
Whereas a soft tissue sarcoma is a rare type of cancer, ac-
counting for approximately 1 percent of all newly diag-
nosed cancers, that arises in the connective tissue of the 
body; 
Whereas the National Institutes of Health designates sar-
coma as a rare form of cancer, with sarcoma containing 
approximately 70 different subtypes; 
Whereas sarcomas are largely resistant to current chemo-
therapy agents, immunotherapy agents, and radiation 
VerDate Sep 11 2014 
01:00 Jun 29, 2017
Jkt 069200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6300
E:\BILLS\HR420.IH
HR420
lotter on DSKBCFDHB2PROD with BILLS
•HRES 420 IH 
therapies, posing a formidable challenge for researchers 
and specialists; 
Whereas sarcoma subtypes have largely not received benefit 
from immunotherapies due to the complexity of the DNA, 
genomes, and mutations associated with the many vari-
ations in the sarcoma subtype landscape; 
Whereas leiomyosarcoma (referred to in this preamble as 
‘‘LMS’’) is a malignant, aggressive subtype of soft tissue 
sarcoma derived from smooth muscle cells typically of 
uterine, gastrointestinal, or soft tissue origin, and can 
metastasize to the bone, spine, brain, and liver; 
Whereas the National Institutes of Health classifies LMS as 
a rare disease, accounting for approximately 15 percent 
of all sarcomas, and LMS itself encompasses at least 4 
different LMS subtypes; 
Whereas LMS primarily affects adults without regard to gen-
der; 
Whereas research and clinical trials for LMS remain com-
plicated, and the prospects for long-term survival remain 
poor; 
Whereas multidisciplinary care coordination teams, because 
of their expertise and experience, are critical to the 
health of sarcoma and LMS patients; 
Whereas sarcoma and LMS research will allow medical pro-
fessionals to improve the quality of care for affected pa-
tients, lead to better clinical outcomes, and promote 
longer survival for patients; and 
Whereas increased education and awareness about sarcoma 
and LMS will contribute to the well-being of the commu-
nities of the United States: Now, therefore, be it 
VerDate Sep 11 2014 
01:00 Jun 29, 2017
Jkt 069200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6300
E:\BILLS\HR420.IH
HR420
lotter on DSKBCFDHB2PROD with BILLS
•HRES 420 IH 
Resolved, That the House of Representatives— 
(1) supports the designation of ‘‘Sarcoma 
Awareness Week’’; 
(2) supports the designation of ‘‘Leiomyosarco-
ma Awareness Day’’; 
(3) recognizes the challenges faced by sarcoma 
and leiomyosarcoma patients; and 
(4) commends the dedication of organizations, 
volunteers, researchers, and caregivers across the 
country working to improve the quality of life of sar-
coma and leiomyosarcoma patients and their fami-
lies. 
Æ 
VerDate Sep 11 2014 
01:00 Jun 29, 2017
Jkt 069200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6301
E:\BILLS\HR420.IH
HR420
lotter on DSKBCFDHB2PROD with BILLS